Table of Content

1 Market Guides 
1.1 Cancer Panel Market - Strategic Situation Analysis & COVID Update
1.2 Large Comprehensive Cancer Panel Market - Situation Analysis 
1.3 Guide for Executives, Marketing, Sales and Business Development Staff 
1.4 Guide for Management Consultants and Investment Advisors 
1.5 Market Size and Shares - Large Comprehensive 

2 Introduction and Market Definition 
2.1 What are Cancer Gene Panels and Profiling? 
2.2 The Sequencing Revolution 
2.3 Market Definition 
2.3.1 Revenue Market Size
2.4 Methodology 
2.4.1 Authors 
2.4.2 Sources 
2.5 A Spending Perspective on Clinical Laboratory Testing 
2.5.1 An Historical Look at Clinical Testing 

3 Market Overview
3.1 Players in a Dynamic Market
3.1.1 Academic Research Lab 
3.1.2 Diagnostic Test Developer
3.1.3 Instrumentation Supplier 
3.1.4 Distributor and Reagent Supplier 
3.1.5 Independent Testing Lab 
3.1.6 Public National/regional lab 
3.1.7 Hospital lab 
3.1.8 Physician Office Labs 
3.1.9 Audit Body 
3.1.10 Certification Body 
3.2 Oncogenomics 
3.2.1 Carcinogenesis
3.2.2 Chromosomes, Genes and Epigenetics 
3.2.2.1 Chromosomes
3.2.2.2 Genes 
3.2.2.3 Epigenetics 
3.2.3 Cancer Genes 
3.2.4 Germline vs Somatic 
3.2.5 Gene Panels, Single Gene Assays and Multiplexing 
3.2.6 Genomic Profiling 
3.2.7 The Comprehensive Assay 
3.2.8 Changing Clinical Role 
3.2.9 The Cancer Screening Market Opportunity 
3.3 Cancer Management vs. Diagnosis
3.3.1 The Role of Risk Assessment 
3.3.2 Diagnosis 
3.3.3 Managing 
3.3.4 Monitoring 
3.4 Phases of Adoption - Looking into The Future 
3.5 Structure of Industry Plays a Part
3.5.1 Hospital Testing Share 
3.5.2 Economies of Scale 
3.5.2.1 Hospital vs. Central Lab
3.5.3 Physician Office Lab’s
3.5.4 Physician’s and POCT 
3.6 Currently Available Large Comprehensive Assays 
3.7 Pricing Profiling vs. Whole Exome (or Genome) Sequencing 
3.7.1 Medicare Profile Pricing 
3.7.2 Whole Exome Sequencing 

4 Market Trends 
4.1 Factors Driving Growth 
4.1.1 Level of Care 
4.1.2 Companion Dx 
4.1.3 Immuno-oncology
4.1.4 Liability 
4.1.5 Aging Population
4.2 Factors Limiting Growth 
4.2.1 State of knowledge 
4.2.2 Genetic Blizzard 
4.2.3 Protocol Resistance 
4.2.4 Regulation and coverage 
4.3 Instrumentation and Automation 
4.3.1 Instruments Key to Market Share 
4.3.2 Bioinformatics Plays a Role 
4.4 Diagnostic Technology Development 
4.4.1 Next Generation Sequencing Fuels a Revolution 
4.4.2 Single Cell Genomics Changes the Picture 
4.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
4.4.4 CGES Testing, A Brave New World 
4.4.5 Biochips/Giant magneto resistance based assay

5 Cancer Panels & Profiles Recent Developments 
5.1 Recent Developments - Importance and How to Use This Section 
5.1.1 Importance of These Developments 
5.1.2 How to Use This Section 
5.2 Dante Labs Acquires Cambridge Cancer Genomics 
5.3 Celemics, Strand Partner on Integrated Platform for NGS Analysis 
5.4 Myriad Genetics Recalibrates Breast Cancer Panel for All Ancestries
5.5 Burning Rock Revenues Rise
5.6 Caris Life Sciences to Expand Liquid Biopsy Testing 
5.7 OncoDiag Announces Multiplex Test for Bladder Cancer Recurrence 
5.8 Intermountain and Myriad Combine Test Offering 
5.9 Illumina, Geneseeq to Offer Cancer Testing Kits in China
5.10 Exact Sciences to Offer End-to-End Cancer Testing 
5.11 Guardant Health Turns to Tumor Tissue Sequencing 
5.12 Tempus Inks Oncology Testing Collaboration With Bayer
5.13 Biocartis Collaborating With GeneproDx, Endpoint Health on Tests for Idylla Platform
5.14 Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test 
5.15 Metastatic Cancer Markers Identified in Clinical WGS Study
5.16 Stitch Bio Bets on CRISPR Tech 
5.17 Bayer, LifeLabs Launch Free NTRK Genetic Testing Program 
5.18 Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Dx
5.19 Progress, Challenges in Liquid Biopsy Reimbursement 
5.20 Israeli Startup Curesponse Raises $6M 
5.21 Invitae, ArcherDX Merge to Advance Precision Oncology Offerings 
5.22 MD Anderson Precision Oncology Decision Support to Use Philips' Informatics Solution
5.23 NeoGenomics, Lilly Oncology Partner for Thyroid Cancer Testing Program 
5.24 Germline Results Guides Precision Therapy in Advanced Cancer 
5.25 FDA Clears Cancer Genomic Profiling Kit From Personal Genome Diagnostics 
5.26 ArcherDX, Premier Collaborate to Evaluate Genomic Sequencing Assay for Cancers
5.27 Labs Reporting Cancer Risk Mutations from Tumor Testing 
5.28 Users Begin Integrating Genomics Data for Clinical Decision Support
5.29 Fujitsu Improves Efficiency in Cancer Genomic Medicine 
5.30 Thermo Fisher's automated sequencer to offer same-day, pan-cancer test results 
5.31 Universal Genetic Testing for All Breast Cancer Patients 
5.32 Exact Sciences buys Genomic Health 
5.33 Multi-Gene Liquid Biopsy Breast Cancer Panel 
5.34 Thrive to Develop Earlier Detection of Multiple Cancer Types 
5.35 New Gene Panel Identifies High Risk Prostate Cancer 
5.36 Guardant Health Liquid Biopsy Test to be Covered by EviCore 
5.37 Biocept Partnership Offering for Liquid Biopsy Adds Several Key Services 
5.38 Natera Commercializes Tumor Whole Exome Sequencing from Plasma 
5.39 Inivata Completes £39.8M Series B Funding Round 
5.40 Bio-Rad Clinical ddPCR Test, Diagnostic System Get FDA Clearance 
5.41 CellMax, Medigen Biotech Partner in Colorectal Cancer Clinical Trials 
5.42 Biodesix Acquires Integrated Diagnostics 
5.43 Predicine, Kintor Pharmaceuticals Partner on Clinical Trials, CDx 

6 Profiles of Key Players 
6.1 10x Genomics, Inc
6.2 Abbott Diagnostics 
6.3 AccuraGen Inc
6.4 Adaptive Biotechnologies
6.5 Aethlon Medical 
6.6 Agena Bioscience, Inc
6.7 Agilent/Dako 
6.8 Anchor Dx 
6.9 ANGLE plc 
6.10 ApoCell, Inc. 
6.11 ArcherDx, Inc
6.12 ARUP Laboratories
6.13 Asuragen
6.14 AVIVA Biosciences 
6.15 Baylor Miraca Genetics Laboratories 
6.16 Beckman Coulter Diagnostics 
6.17 Becton, Dickinson and Company 
6.18 BGI Genomics Co. Ltd 
6.19 Bioarray Genetics
6.20 Biocartis 
6.21 Biocept, Inc 
6.22 Biodesix Inc
6.23 BioFluidica 
6.24 BioGenex 
6.25 BioIVT 
6.26 Biolidics Ltd
6.27 bioMérieux Diagnostics
6.28 Bioneer Corporation 
6.29 Bio-Rad Laboratories, Inc
6.30 Bio-Reference Laboratories
6.31 Bio-Techne 
6.32 Bioview 
6.33 Bolidics 
6.34 Boreal Genomics 
6.35 Bristol-Myers Squibb
6.36 Burning Rock 
6.37 Cancer Genetics 
6.38 Caris Molecular Diagnostics 
6.39 Castle Biosciences, Inc. 
6.40 Celemics 
6.41 CellMax Life 
6.42 Cepheid (Danaher) 
6.43 Charles River Laboratories 
6.44 Chronix Biomedical 
6.45 Circulogene
6.46 Clinical Genomics 
6.47 Cynvenio
6.48 Cytolumina Technologies Corp
6.49 CytoTrack 
6.50 Datar Cancer Genetics Limited 
6.51 Diagnologix LLC
6.52 Diasorin S.p.A
6.53 Enzo Life Sciences, Inc
6.54 Epic Sciences 
6.55 Epigenomics AG
6.56 Eurofins Scientific 
6.57 Exact Sciences 
6.58 Exosome Diagnostics 
6.59 Exosome Sciences
6.60 Fabric Genomics 
6.61 Fluidigm Corp 
6.62 Fluxion Biosciences 
6.63 Foundation Medicine 
6.64 Freenome 
6.65 FUJIFILM Wako Diagnostics
6.66 GeneFirst Ltd. 
6.67 Genetron Holdings 
6.68 GenomOncology
6.69 GILUPI Nanomedizin
6.70 Grail, Inc. 
6.71 Guardant Health 
6.72 HalioDx 
6.73 HansaBiomed 
6.74 HeiScreen 
6.75 Helomics
6.76 Horizon Discovery 
6.77 HTG Molecular Diagnostics 
6.78 iCellate
6.79 Illumina 
6.80 Incell Dx 
6.81 Inivata 
6.82 Integrated Diagnostics 
6.83 Invitae Corporation
6.84 Invivogen 
6.85 Invivoscribe 
6.86 Janssen Diagnostics 
6.87 MDNA Life SCIENCES, Inc
6.88 MDx Health 
6.89 Menarini Silicon Biosystems 
6.90 Millipore Sigma 
6.91 Miltenyi Biotec 
6.92 MIODx 
6.93 miR Scientific
6.94 Molecular MD 
6.95 MyCartis 
6.96 Myriad Genetics/Myriad RBM 
6.97 NantHealth, Inc. 
6.98 Natera 
6.99 NeoGenomics 
6.100 New Oncology 
6.101 NGeneBio 
6.102 Novogene Bioinformatics Technology Co., Ltd. 
6.103 Oncocyte 
6.104 OncoDNA 
6.105 Ortho Clinical Diagnostics 
6.106 Oxford Nanopore Technologies 
6.107 Panagene
6.108 Perkin Elmer 
6.109 Personal Genome Diagnostics
6.110 Personalis
6.111 Precipio 
6.112 PrecisionMed 
6.113 Promega 
6.114 Qiagen Gmbh 
6.115 Rarecells SAS
6.116 RareCyte
6.117 Roche Molecular Diagnostics 
6.118 Screencell 
6.119 Sense Biodetection 
6.120 Serametrix 
6.121 Siemens Healthineers 
6.122 Silicon Biosystems 
6.123 simfo GmbH 
6.124 Singlera Genomics Inc
6.125 Singulomics 
6.126 SkylineDx 
6.127 Stratos Genomics 
6.128 Sysmex Inostics
6.129 Tempus Labs, Inc
6.130 Thermo Fisher Scientific Inc
6.131 Thrive Earlier Detection 
6.132 Todos Medical 
6.133 Trovagene
6.134 Variantyx 
6.135 Volition 
6.136 Vortex Biosciences 

7 The Global Market for Cancer Gene Panels and Profiles
7.1 Global Market Overview by Country 
7.1.1 Table - Global Market by Country
7.1.2 Chart - Global Market by Country 
7.2 Global Market by Cancer Type - Overview 
7.2.1 Table - Global Market by Cancer Type 
7.2.2 Chart - Global Market by Cancer Type - Base/Final Year Comparison 
7.2.3 Chart - Global Market by Cancer Type - Base Year 
7.2.4 Chart - Global Market by Cancer Type - Final Year
7.2.5 Chart - Global Market by Cancer Type - Share by Year 
7.2.6 Chart - Global Market by Cancer Type - Segment Growth 
7.3 Global Market by Application - Overview
7.3.1 Table - Global Market by Application 
7.3.2 Chart - Global Market by Application - Base/Final Year Comparison 
7.3.3 Chart - Global Market by Application - Base Year 
7.3.4 Chart - Global Market by Application - Final Year
7.3.5 Chart - Global Market by Application - Share by Year 
7.3.6 Chart - Global Market by Application - Segment Growth 
7.4 Global Market by Tissue - Overview 
7.4.1 Table - Global Market by Tissue 
7.4.2 Chart - Global Market by Tissue - Base/Final Year Comparison 
7.4.3 Chart - Global Market by Tissue - Base Year 
7.4.4 Chart - Global Market by Tissue - Final Year 
7.4.5 Chart - Global Market by Tissue - Share by Year 
7.4.6 Chart - Global Market by Tissue - Segment Growth
7.5 Global Market Germline & Somatic - Overview
7.5.1 Table - Global Market Germline & Somatic 
7.5.2 Chart - Global Market Germline & Somatic - Base/Final Year Comparison 
7.5.3 Chart - Global Market Germline & Somatic - Base Year 
7.5.4 Chart - Global Market Germline & Somatic - Final Year
7.5.5 Chart - Global Market Germline & Somatic - Share by Year 
7.5.6 Chart - Global Market Germline & Somatic - Segment Growth 

8 Global Cancer Gene Panels & Profiles Markets - By Type of Cancer
8.1 Comprehensive Panels & Profiles 
8.1.1 Table Comprehensive Testing - by Country
8.1.2 Chart - Comprehensive Testing Growth 
8.2 Breast Cancer Gene Testing 
8.2.1 Table Breast Cancer Gene Testing - by Country 
8.2.2 Chart - Breast Cancer Testing Growth
8.3 Colorectal Cancer Gene Testing 
8.3.1 Table Colorectal Cancer Gene Testing - by Country 
8.3.2 Chart - Colorectal Cancer Gene Testing Growth 
8.4 Gynecological Cancer Gene Testing 
8.4.1 Table Gynecological Cancer Gene Testing - by Country 
8.4.2 Chart - Gynecological Cancer Gene Testing Growth
8.5 Blood Cancer Gene Testing
8.5.1 Table Blood Cancer Gene Testing - by Country 
8.5.2 Chart - Blood Cancer Gene Testing Growth 
8.6 Prostate Cancer Gene Testing 
8.6.1 Table Prostate Cancer Gene Testing - by Country 
8.6.2 Chart - Prostate Cancer Testing Growth 
8.7 Lung Cancer Gene Testing 
8.7.1 Table Lung Cancer Gene Testing - by Country
8.7.2 Chart - Lung Cancer Gene Testing Growth 
8.8 Other Cancer Gene Testing
8.8.1 Table Other Cancer Gene Testing - by Country 
8.8.2 Chart - Other Cancer Gene Testing Growth 

9 Global Cancer Gene Panels & Profiles Markets - By Type of Application 
9.1 Clinical Testing
9.1.1 Table Clinical Testing - by Country 
9.1.2 Chart - Clinical Testing Growth
9.2 Pharmaceutical Testing 
9.2.1 Table Pharmaceutical Testing - by Country 
9.2.2 Chart - Pharmaceutical Testing Growth
9.3 Research Testing 
9.3.1 Table Research Testing - by Country 
9.3.2 Chart - Research Testing Growth 

10 Global Cancer Gene Panels & Profiles Markets - By Tissue Type
10.1 Solid Tissue
10.1.1 Table Solid Tissue Testing - by Country 
10.1.2 Chart - Solid Tissue Testing Growth 
10.2 Liquid Tissue Testing 
10.2.1 Table Liquid Tissue Testing - by Country 
10.2.2 Chart - Liquid Tissue Testing Growth

11 Global Cancer Gene Testing Markets - Germline and Somatic 
11.1 Global Market Somatic
11.1.1 Table Somatic - by Country 
11.1.2 Chart - Somatic Testing Growth 
11.2 Global Market Germline 
11.2.1 Table Germline - by Country
11.2.2 Chart - Germline Testing Growth 

12 Potential Market Opportunity Sizes
12.1 Potential Cancer Screening by Country: Lung, Breast & Colorectal
12.2 Potential Cancer Screening by Country: Prostate, Other Cancer & All Cancer 
12.3 Potential Market Size - Cancer Diagnosis 
12.4 Potential Market Size - Therapy Selection

13 Appendices 
13.1 Quarterly Actuals and Forecast Volumes and Revenues for Foundation Medicine and Guardant Health 
13.2 United States Medicare System: January 2021 Clinical Laboratory Fees Schedule 
13.3 FDA Approved Human Genetic Tests 
13.4 Pharmacogenomic Biomarkers in Drug Labeling
13.5 FDA Approved Pharmacogenomics Tests 

List of Tables
Table 1 Market Shares 
Table 2 Medicare Clinical Lab Expenditures Actual & Forecast 2014 to 2024 ($Billion) 
Table 3 Market Players by Type 
Table 4 The Base Pairs
Table 5 Current Assays 
Table 6 Relevant Pricing Table 
Table 7 Five Factors Driving Growth 
Table 8 Four Factors Limiting Growth 
Table 9 Key Diagnostic Laboratory Technology Trends 
Table 10 Next Generation Sequencing Technologies - Speed and Cost 
Table 11 Global Cancer Panel Market by Region
Table 12 Global Market by Cancer Type 
Table 13 Global Market by Application 
Table 14 Global Market by Tissue 
Table 15 Global Market Germline & Somatic 
Table 16 Comprehensive Testing by Country 
Table 17 Breast Cancer Gene Testing by Country 
Table 18 Colorectal Cancer Gene Testing by Country 
Table 19 Gynecological Cancer Testing by Country 
Table 20 Blood Cancer Gene Testing by Country 
Table 21 Prostate Cancer Gene Testing by Country 
Table 22 Lung Cancer Gene Testing by Country 
Table 23 Other Cancer Gene Testing by Country 
Table 24 Clinical Testing by Country 
Table 25 Pharmaceutical Testing by Country 
Table 26 Research Testing by Country
Table 27 Solid Tissue Testing by Country 
Table 28 Liquid Tissue Testing by Country 
Table 29 Somatic by Country 
Table 30 Germline by Country 
Table 31 Potential Screening Market: Lung, Breast & Colorectal 
Table 32 Potential Screening Market: Prostate, Other & All 
Table 33 Potential Cancer Diagnosis Market Size 
Table 34 Potential Cancer Management Market Size 
Table 35 Foundation - Guardant 2016-17 Quarterly Revenue & Volume 
Table 36 Foundation - Guardant 2018 Quarterly Revenue & Volume 
Table 37 Foundation - Guardant 2019 Quarterly Revenue & Volume 
Table 38 Foundation - Guardant 2020 Quarterly Revenue & Volume 
Table 39 Foundation - Guardant 2021 Quarterly Revenue & Volume 
Table 40 2021 Laboratory Fee Schedule 
Table 41 FDA Approved Human Genetic tests 
Table 42 Pharmacogenomic Biomarkers 
Table 43 FDA Approved Pharmacogenomic Tests 

List of Figures
Figure 1 Large Comprehensive Profiles - Company Market Shares Chart 
Figure 2 VistSeq Hereditary Cancer Panel
Figure 3 Medicare Clinical Lab Expenditures 2014 to 2024 ($Million) 
Figure 4 The Genomic Progression of Cancer
Figure 5 DNA Strands and Chromosomes 
Figure 6 Karyogram of Human Chromosomes 
Figure 7 Size of Various Genomes 
Figure 8 Germline vs Somatic Mutations
Figure 9 Comparing Genomic Diagnostic and Traditional Testing 
Figure 10 Percentage of World Population Over 65 
Figure 11 Base Year Country Global Share 
Figure 12 Global Market by Cancer - Base vs. Final Year 
Figure 13 Cancer Panel Market Base Year
Figure 14 Cancer Panel Market Final Year 
Figure 15 Cancer Type Share by Year 
Figure 16 Cancer Type Segment Growth 
Figure 17 Global Market by Cancer - Base vs. Final Year 
Figure 18 Cancer Panel Market Base Year
Figure 19 Cancer Panel Market Final Year 
Figure 20 Application Share by Year
Figure 21 Application Segment Growth 
Figure 22 Global Market by Cancer - Base vs. Final Year 
Figure 23 Cancer Panel Market Base Year
Figure 24 Cancer Panel Market Final Year 
Figure 25 Tissue Share by Year 
Figure 26 Tissue Segment Growth 
Figure 27 Germline & Somatic - Base vs. Final Year 
Figure 28 Germline & Somatic Market Base Year 
Figure 29 Germline & Somatic Market Final Year 
Figure 30 Germline & Somatic Share by Year 
Figure 31 Germline & Somatic Segment Growth 
Figure 32 Comprehensive Testing Growth 
Figure 33 Breast Cancer Testing Growth
Figure 34 Colorectal Cancer Gene Testing Growth 
Figure 35 Gynecological Cancer Testing Growth 
Figure 36 Blood Cancer Gene Testing Growth 
Figure 37 Prostate Cancer Gene Testing Growth 
Figure 38 Lung Cancer Gene Testing Growth 
Figure 39 Other Cancer Gene Testing Growth 
Figure 40 Clinical Testing Growth 
Figure 41 Pharmaceutical Testing Growth
Figure 42 Research Testing Growth 
Figure 43 Solid Tissue Testing Growth
Figure 44 Liquid Tissue Testing Growth 
Figure 45 Somatic Testing Growth 
Figure 46 Germline Testing Growth